Revelation Biosciences reports $1.9 million net loss for Q3 2025

Reuters11-07

<a href="https://laohu8.com/S/REVBU">Revelation Biosciences</a> reports $1.9 million net loss for Q3 2025

Revelation Biosciences Inc. reported a net loss of $1.9 million, or $(1.77) per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $(40.2) per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $(354.1) per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097873) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581048729?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581048729","market":"nz","top_or_hot":-1,"title":"Revelation Biosciences reports $1.9 million net loss for Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> reports $1.9 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc. reported a net loss of $1.9 million, or $(1.77) per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $(40.2) per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $(354.1) per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a> Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097873) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revelation Biosciences reports $1.9 million net loss for Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevelation Biosciences reports $1.9 million net loss for Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/REVBU\">Revelation Biosciences</a> reports $1.9 million net loss for Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/REVB\">Revelation Biosciences</a> Inc. reported a net loss of $1.9 million, or $(1.77) per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $(40.2) per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $(354.1) per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/REVBW\">Revelation Biosciences</a> Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097873) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REVB","symbol_name":"Revelation Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9cCY6M:1","article_id":"2581048729","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581048729","pubTimestamp":1762464420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revelation Biosciences Inc. reported a net loss of $1.9 million, or $ per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $ per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $ per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REVB":"Revelation Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Revelation Biosciences报告2025年第三季度净亏损190万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REVB":0.9},"content_text":"Revelation Biosciences reports $1.9 million net loss for Q3 2025\n    \n\nRevelation Biosciences Inc. reported a net loss of $1.9 million, or $(1.77) per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $(40.2) per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $(354.1) per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1097873) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581048729","isCrawlerRequest":true}